Odanacatib

Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K.

Product Specifications

CAS Number

[603139-19-1]

Product Name Alternative

MK-0822

UNSPSC

12352005

Hazard Statement

H373

Target

Cathepsin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Odanacatib.html

Concentration

10mM

Purity

99.80

Solubility

DMSO : ≥ 25 mg/mL

Smiles

N#CC1(NC([C@@H](N[C@H](C(F)(F)F)C2=CC=C(C3=CC=C(S(=O)(C)=O)C=C3)C=C2)CC(C)(F)C)=O)CC1

Molecular Formula

C25H27F4N3O3S

Molecular Weight

525.56

Precautions

H373

References & Citations

[1]Jacques Yves Gauthier, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18 (3) :923-8.|[2]Leung P, et al. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011 Oct;49 (4) :623-635.|[3]Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging. 2012;7:235-47.|[4]Yi C, et al. Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats. Sci Rep. 2017 Mar 17;7:44682.